Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Recurrent lung nodules as a presentation of ventricular septal defect-related endocarditis.

Trytell A, Darby J, Conron M, Newcomb A, Burns A.

Respirol Case Rep. 2019 Jun 1;7(6):e00446. doi: 10.1002/rcr2.446. eCollection 2019 Aug.

2.

Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia.

Mileshkin L, Dunn C, Cross H, Duffy M, Shaw M, Antippa P, Mitchell P, Akhurst T, Conron M, Moore M, Philip J, Bartlett J, Emery J, Zambello B.

Intern Med J. 2018 Dec 4. doi: 10.1111/imj.14183. [Epub ahead of print]

PMID:
30515932
3.

Outcomes following resection of non-small cell lung cancer in octogenarians.

Vazirani J, Moraes J, Barnett S, Johnson DF, Knight S, Miller A, Wright G, Alam NZ, Conron M, Irving LB, Antippa P, Steinfort DP.

ANZ J Surg. 2018 Dec;88(12):1322-1327. doi: 10.1111/ans.14861. Epub 2018 Oct 2.

PMID:
30277303
4.

The 2016 Melbourne thunderstorm asthma epidemic: Risk factors for severe attacks requiring hospital admission.

Hew M, Lee J, Susanto NH, Prasad S, Bardin PG, Barnes S, Ruane L, Southcott AM, Gillman A, Young A, Rangamuwa K, O'Hehir RE, McDonald C, Sutherland M, Conron M, Matthews S, Harun NS, Lachapelle P, Douglass JA, Irving L, Langton D, Mann J, Erbas B, Thien F.

Allergy. 2019 Jan;74(1):122-130. doi: 10.1111/all.13609. Epub 2018 Oct 11.

PMID:
30243030
5.

Sex-Dependent Staging in Non-Small-Cell Lung Cancer; Analysis of the Effect of Sex Differences in the Eighth Edition of the Tumor, Node, Metastases Staging System.

Wainer Z, Wright GM, Gough K, Daniels MG, Russell PA, Choong P, Conron M, Ball D, Solomon B.

Clin Lung Cancer. 2018 Nov;19(6):e933-e944. doi: 10.1016/j.cllc.2018.08.004. Epub 2018 Aug 22.

PMID:
30206043
6.

The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors.

Thien F, Beggs PJ, Csutoros D, Darvall J, Hew M, Davies JM, Bardin PG, Bannister T, Barnes S, Bellomo R, Byrne T, Casamento A, Conron M, Cross A, Crosswell A, Douglass JA, Durie M, Dyett J, Ebert E, Erbas B, French C, Gelbart B, Gillman A, Harun NS, Huete A, Irving L, Karalapillai D, Ku D, Lachapelle P, Langton D, Lee J, Looker C, MacIsaac C, McCaffrey J, McDonald CF, McGain F, Newbigin E, O'Hehir R, Pilcher D, Prasad S, Rangamuwa K, Ruane L, Sarode V, Silver JD, Southcott AM, Subramaniam A, Suphioglu C, Susanto NH, Sutherland MF, Taori G, Taylor P, Torre P, Vetro J, Wigmore G, Young AC, Guest C.

Lancet Planet Health. 2018 Jun;2(6):e255-e263. doi: 10.1016/S2542-5196(18)30120-7.

7.

EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.

Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Solomon B, Dobrovic A, McLachlan SA, Moore MM.

Med Oncol. 2017 Sep 6;34(10):175. doi: 10.1007/s12032-017-1031-1.

PMID:
28879441
8.

Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients.

Russell PA, Rogers TM, Solomon B, Alam N, Barnett SA, Rathi V, Williams RA, Wright GM, Conron M.

Pathology. 2017 Oct;49(6):604-610. doi: 10.1016/j.pathol.2017.07.002. Epub 2017 Aug 12.

PMID:
28811082
9.

Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer.

Alexander M, Wolfe R, Ball D, Conron M, Stirling RG, Solomon B, MacManus M, Officer A, Karnam S, Burbury K, Evans SM.

Br J Cancer. 2017 Aug 22;117(5):744-751. doi: 10.1038/bjc.2017.232. Epub 2017 Jul 20.

10.

Lung cancer and socio-economic status: inextricably linked to place of residence.

Denton EJ, Hart D, Russell PA, Wright G, Conron M.

Intern Med J. 2017 May;47(5):563-569. doi: 10.1111/imj.13376.

PMID:
28105777
11.

Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens.

Rathi V, Wright G, Constantin D, Chang S, Pham H, Jones K, Palios A, Mclachlan SA, Conron M, McKelvie P, Williams R.

Pathology. 2017 Jan;49(1):75-82. doi: 10.1016/j.pathol.2016.08.016. Epub 2016 Nov 30.

PMID:
27913044
12.

Impact of sex on prognostic host factors in surgical patients with lung cancer.

Wainer Z, Wright GM, Gough K, Daniels MG, Choong P, Conron M, Russell PA, Alam NZ, Ball D, Solomon B.

ANZ J Surg. 2017 Dec;87(12):1015-1020. doi: 10.1111/ans.13728. Epub 2016 Sep 14.

PMID:
27625078
13.

Nephrology: Instructive case haemorrhagic cystitis due to BK virus in an adult with cardiac & pulmonary sarcoidosis.

Martin WG, Clarke D, Conron M, MacIsaac A, Hill P, Goodman DJ.

Nephrology (Carlton). 2016 Sep;21(9):793. doi: 10.1111/nep.12696. No abstract available.

PMID:
27546780
14.

Changing trends in diagnosis, staging, treatment and survival in lung cancer: comparison of three consecutive cohorts in an Australian lung cancer centre.

Denton EJ, Hart D, Wainer Z, Wright G, Russell PA, Conron M.

Intern Med J. 2016 Aug;46(8):946-54. doi: 10.1111/imj.13132.

PMID:
27177600
15.

Improving outcomes in lung cancer: the value of the multidisciplinary health care team.

Denton E, Conron M.

J Multidiscip Healthc. 2016 Mar 30;9:137-44. doi: 10.2147/JMDH.S76762. eCollection 2016. Review.

16.

Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations.

Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Dobrovic A, Moore MM, McLachlan SA.

Pathology. 2016 Jan;48(1):17-24. doi: 10.1016/j.pathol.2015.11.002. Epub 2015 Dec 12.

PMID:
27020204
17.

The Victorian Lung Cancer Registry pilot: improving the quality of lung cancer care through the use of a disease quality registry.

Stirling RG, Evans SM, McLaughlin P, Senthuren M, Millar J, Gooi J, Irving L, Mitchell P, Haydon A, Ruben J, Conron M, Leong T, Watkins N, McNeil JJ.

Lung. 2014 Oct;192(5):749-58. doi: 10.1007/s00408-014-9603-8. Epub 2014 Jun 8.

PMID:
24907066
18.

Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH.

Russell PA, Yu Y, Young RJ, Conron M, Wainer Z, Alam N, Solomon B, Wright GM.

Mod Pathol. 2014 Dec;27(12):1621-31. doi: 10.1038/modpathol.2014.71. Epub 2014 Apr 25.

19.

The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma.

Clay TD, Do H, Sundararajan V, Moore MM, Conron M, Wright GM, McLachlan SA, Dobrovic A, Russell PA.

J Thorac Oncol. 2014 May;9(5):654-63. doi: 10.1097/JTO.0000000000000150.

20.

Acceptability of early integration of palliative care in patients with incurable lung cancer.

Le BH, Mileshkin L, Doan K, Saward D, Spruyt O, Yoong J, Gunawardana D, Conron M, Philip J.

J Palliat Med. 2014 May;17(5):553-8. doi: 10.1089/jpm.2013.0473. Epub 2014 Mar 3.

PMID:
24588685
21.

EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinoma.

Russell PA, Yu Y, Do H, Clay TD, Moore MM, Wright GM, Conron M, Wainer Z, Dobrovic A, McLachlan SA.

Pathology. 2014 Jan;46(1):32-6. doi: 10.1097/PAT.0000000000000027.

PMID:
24300726
22.

The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer.

Alamgeer M, Ganju V, Szczepny A, Russell PA, Prodanovic Z, Kumar B, Wainer Z, Brown T, Schneider-Kolsky M, Conron M, Wright G, Watkins DN.

Thorax. 2013 Dec;68(12):1095-104. doi: 10.1136/thoraxjnl-2012-203021. Epub 2013 Jul 22.

23.

Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.

Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D, John T.

J Thorac Oncol. 2013 Apr;8(4):461-8. doi: 10.1097/JTO.0b013e3182828fb8.

24.

Sex and SUVmax: sex-dependent prognostication in early non-small cell lung cancer.

Wainer Z, Daniels MG, Callahan J, Binns D, Hicks RJ, Antippa P, Russell PA, Alam NZ, Conron M, Solomon B, Wright GM.

J Nucl Med. 2012 Nov;53(11):1676-85. doi: 10.2967/jnumed.112.105197. Epub 2012 Sep 14.

26.

Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer.

Newnham GM, Conron M, McLachlan S, Dobrovic A, Do H, Li J, Opeskin K, Thompson N, Wright GM, Thomas DM.

BMC Cancer. 2011 Mar 7;11:93. doi: 10.1186/1471-2407-11-93.

27.

Endoscopic ultrasound guided fine needle aspiration (EUS-FNA) of mediastinal lesions.

Nguyen TQ, Kalade A, Prasad S, Desmond P, Wright G, Hart D, Conron M, Chen RY.

ANZ J Surg. 2011 Jan;81(1-2):75-8. doi: 10.1111/j.1445-2197.2010.05266.x.

PMID:
21299803
28.

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sänger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nürnberg P, Perner S, Thomas RK.

Sci Transl Med. 2010 Dec 15;2(62):62ra93. doi: 10.1126/scitranslmed.3001451. Erratum in: Sci Transl Med. 2012 Apr 18;4(130):130er2. Sci Transl Med. 2011 Jan 19;3(66):66er2.

29.

Cost-benefit of minimally invasive staging of non-small cell lung cancer: a decision tree sensitivity analysis.

Steinfort DP, Liew D, Conron M, Hutchinson AF, Irving LB.

J Thorac Oncol. 2010 Oct;5(10):1564-70. doi: 10.1097/JTO.0b013e3181e8b2e6.

30.

Endobronchial ultrasound-guided transbronchial needle aspiration for the evaluation of suspected lymphoma.

Steinfort DP, Conron M, Tsui A, Pasricha SR, Renwick WE, Antippa P, Irving LB.

J Thorac Oncol. 2010 Jun;5(6):804-9.

31.

Small changes in six-minute walk distance are important in diffuse parenchymal lung disease.

Holland AE, Hill CJ, Conron M, Munro P, McDonald CF.

Respir Med. 2009 Oct;103(10):1430-5. doi: 10.1016/j.rmed.2009.04.024. Epub 2009 May 23.

32.

Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians.

Mangat P, Conron M, Gabbay E, Proudman SM; Pulmonary Interstitial Vascular Organisational Taskforce (PIVOT).

Intern Med J. 2010 Jul;40(7):494-502. doi: 10.1111/j.1445-5994.2009.01990.x. Epub 2009 May 21.

PMID:
19460060
33.
34.

Molecular profiling of non-small cell lung cancer: of what value in clinical practice?

Newnham GM, Thomas DM, McLachlan SA, Wright G, Conron M.

Heart Lung Circ. 2008 Dec;17(6):451-62. doi: 10.1016/j.hlc.2007.11.144. Epub 2008 Jul 26. Review.

PMID:
18676201
35.

Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease.

Holland AE, Hill CJ, Conron M, Munro P, McDonald CF.

Thorax. 2008 Jun;63(6):549-54. doi: 10.1136/thx.2007.088070. Epub 2008 Feb 1.

PMID:
18245143
36.

Analysis of multidisciplinary lung cancer practice.

Conron M, Phuah S, Steinfort D, Dabscheck E, Wright G, Hart D.

Intern Med J. 2007 Jan;37(1):18-25.

PMID:
17199840
38.

Validity of the Assessment of Quality of Life (AQoL) utility instrument in patients with operable and inoperable lung cancer.

Manser RL, Wright G, Byrnes G, Hart D, Conron M, Carter R, McLachlan SA, Campbell DA.

Lung Cancer. 2006 Aug;53(2):217-29. Epub 2006 Jun 12.

PMID:
16765475
39.

The accuracy of EUS-FNA in assessing mediastinal lymphadenopathy and staging patients with NSCLC.

Caddy G, Conron M, Wright G, Desmond P, Hart D, Chen RY.

Eur Respir J. 2005 Mar;25(3):410-5.

40.

Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment.

Sahhar J, Littlejohn G, Conron M.

Intern Med J. 2004 Nov;34(11):626-38. Review.

PMID:
15546457
41.

Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

Foxwell B, Andreakos E, Brennan F, Feldmann M, Smith C, Conron M.

Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii90-3. Review. No abstract available.

42.

Nuclear factor-kappaB activation in alveolar macrophages requires IkappaB kinase-beta, but not nuclear factor-kappaB inducing kinase.

Conron M, Andreakos E, Pantelidis P, Smith C, Beynon HL, Dubois RM, Foxwell BM.

Am J Respir Crit Care Med. 2002 Apr 1;165(7):996-1004.

PMID:
11934728
43.

Sarcoidosis.

Hart LA, Conron M, du Bois RM.

Int J Tuberc Lung Dis. 2001 Sep;5(9):791-806. Review.

PMID:
11573890
44.

Alveolar macrophages and T cells from sarcoid, but not normal lung, are permissive to adenovirus infection and allow analysis of NF-kappa b-dependent signaling pathways.

Conron M, Bondeson J, Pantelidis P, Beynon HL, Feldmann M, duBois RM, Foxwell BM.

Am J Respir Cell Mol Biol. 2001 Aug;25(2):141-9.

PMID:
11509322
45.

Immunological mechanisms in sarcoidosis.

Conron M, Du Bois RM.

Clin Exp Allergy. 2001 Apr;31(4):543-54. Review. No abstract available.

PMID:
11359421
46.

Churg-Strauss syndrome presenting with visual loss.

Carmichael J, Conron M, Beynon H, Crow J, Warner TT.

Rheumatology (Oxford). 2000 Dec;39(12):1433-4. No abstract available.

PMID:
11136895
47.

Ketoconazole for the treatment of refractory hypercalcemic sarcoidosis.

Conron M, Beynon HL.

Sarcoidosis Vasc Diffuse Lung Dis. 2000 Oct;17(3):277-80.

PMID:
11033844
48.

Churg-Strauss syndrome.

Conron M, Beynon HL.

Thorax. 2000 Oct;55(10):870-7. Review. No abstract available.

49.

Calcium metabolism in sarcoidosis and its clinical implications.

Conron M, Young C, Beynon HL.

Rheumatology (Oxford). 2000 Jul;39(7):707-13.

PMID:
10908687

Supplemental Content

Loading ...
Support Center